PharmaMar wanted to highlight the growth in royalty income, which has increased by 8% compared to the same period of the previous year, reaching a total...
Pharma Mar has decided to liquidate its diagnostic subsidiary Genomics, as part of their strategy to focus on their core activity of drug development and marketing....